Phase III Study (MM-020/IFM 07-01) of Oral REVLIMID® (Lenalidomide) in Newly-Diagnosed Multiple Myeloma Meets Primary Endpoint
Statistically significant improvement in progression-free survival demonstrated On Thursday 11 July 2013, Celgene International Sàrl announced that its phase III study (MM-020/IFM 07-01) of REVLIMID® (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival (PFS). In the study, a doublet regimen of continuous oral lenalidomide in combination with low-dose dexamethasone (Rd) demonstrated a statistically significant improvement in PFS compared to patients receiving a comparator arm…